{"data":{"ModuleTitle":{"label":"Module Title","value":"Company Description"},"CompanyName":{"label":"Company Name","value":"Zentalis Pharmaceuticals, Inc."},"Symbol":{"label":"Symbol","value":"ZNTL"},"Address":{"label":"Address","value":"1359 BROADWAY,SUITE 1710, NEW YORK, New York, 10018, United States"},"Phone":{"label":"Phone","value":"+1 212 433-3791"},"Industry":{"label":"Industry","value":"Biotechnology: Pharmaceutical Preparations"},"Sector":{"label":"Sector","value":"Health Care"},"Region":{"label":"Region","value":"North America"},"CompanyDescription":{"label":"Company Description","value":"Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers. It uses a drug discovery engine, which it refers to as Integrated Discovery Engine, to identify targets and develop small molecule new chemical entities, or NCEs, with properties that it believes could result in potentially differentiated product profiles. It has two lead product candidates under pipeline: ZN-c5, for the treatment of advanced estrogen receptor-positive, human epidermal growth factor receptor 2-negative, or ER+/HER2-, advanced or metastatic breast cancer; and ZN-c3, for the treatment of advanced solid tumors as monotherapy and ovarian cancer."},"CompanyUrl":{"label":"Company Url","value":"https://www.zentalis.com"},"KeyExecutives":{"label":"Key Executives","value":[{"name":"Mark Lackner","title":"Chief Scientific Officer"}]}},"message":null,"status":{"rCode":200,"bCodeMessage":null,"developerMessage":null}}